Abeona Therapeutics prices $75M underwritten offering of common stock and pre-funded warrants

ABEONA THERAPEUTICS INC.

Offering: 12,285,056 common shares at $4.07/share and 6,142,656 pre-funded warrants at $4.0699 each.
Gross proceeds ~$75M; net proceeds ~$70.2M after underwriting discounts and expenses.
Closing expected May 7, 2024; Stifel is sole bookrunner.
Proceeds to fund BLA resubmission and commercialization of pz-cel, plus working capital.
New and existing investors participating include Adage Capital, Janus Henderson, Nantahala, Suvretta, Vivo Capital.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ABEONA THERAPEUTICS INC. entered into Underwriting Agreement with Stifel, Nicolaus & Company, Incorporated valued at $70.2 million (effective 2024-05-03).

Action: entry
Agreement: underwriting
Counterparty: Stifel, Nicolaus & Company, Incorporated
Value: $70.2 million
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, Abeona Therapeutics Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Stifel, Nicolaus & Company, Incorporated (the “Underwriter”) relating to the issuance and sale of an aggregate of (a) 12,285,056 shares of the Company’s common stock (the “Shares”), and (b) pre-funded warrants to purchase 6,142,656 shares of the Company’s common stock (the “Pre-Funded Warrants”) in an underwritten offering (the “Offering”).

View on SEC.gov

292 material agreements filed in the last 30 days. Browse all material agreements →

ABEONA THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-017768

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.